4/ A 2001 open-label RCT looked at torsemide vs furosemide in 234 patients hospitalized with a history of heart failure. At 1 year, ≥1 readmission occurred in:
7/ The ongoing TRANSFORM-HF should provide a more definitive answer.
This study is randomizing patients hospitalized with heart failure to torsemide or furosemide prior to discharge. It aims to enroll 6000 patients and be completed by August 2022.
14/ Collectively, there is good support for the idea that torsemide does more than simply promote natriuresis/diuresis.
Whether these additional effects lead to observed differences in patient-centered outcomes isn't as clear.
15/15 SUMMARY
⚡️Available evidence favors torsemide over furosemide
⚡️Torsemide has better pharmacokinetics and a longer duration of action
⚡️Torsemide may be more than a loop diuretic!
• • •
Missing some Tweet in this thread? You can try to
force a refresh
🔑 It is highly variable (ranging from 11-100%) even in those without heart failure
🔑 This variability is both between patients and within the same patient
More specifically, Pearl's study sample contained an overrepresentation of exposed controls (i.e., control subjects who had died from tuberculosis).
This led to an incorrect conclusion that tuberculosis is associated with decreased rates of cancer.
Pearl published a "retraction" in Science.
While arguing that "any serious student of the matter" would agree that TB and cancer are rarely found together in the same person, he admits that concluding a mechanistic connection "may have been erroneous".
1/16
Why do we use a vaccine (BCG) to treat an unrelated malignancy (bladder cancer)?
Can infections really prevent/treat cancer?
Let's find out.
2/ This story begins in 1813 when Arsène-Hippolyte Vautier reported that patients suffering from gas gangrene experienced a decrease in the size of their malignant tumors.
An explanation (or even the causative bacterium!) wasn't immediately apparent.